Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year.
Novo Nordisk has also spoken out strongly against Hims & Hers’ compounded Wegovy pill, with CEO Maziar Mike Doustdar telling investors the knockoff version is a waste of money.
The agency incorrectly labeled some taxpayers as hostages when providing tax relief, or failed to remove a special indicator after their release from captivity.
Accrual, a tax prep and review platform for firms that launched today with $75 million in funding, already supports every federal and state tax form, as well as the unstructured data to fill it.
The Auditing Standards Board will be proposing a set of updates to its attestation standards to address sustainability information and other assurance issues.
Accrual is part of General Catalyst’s $1.5 billion Creation fund for startups building AI tools for industries not typically first adopters of new technology.